Matt Larew

Stock Analyst at William Blair

(0.76)
# 4,061
Out of 5,127 analysts
15
Total ratings
50%
Success rate
-17.52%
Average return

Stocks Rated by Matt Larew

Waters
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $396.65
Upside: -
Charles River Laboratories International
Oct 6, 2025
Upgrades: Outperform
Price Target: n/a
Current: $215.51
Upside: -
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $606.50
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.47
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.85
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $9.06
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $122.44
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $64.58
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.06
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $5.48
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $34.74
Upside: -